In the second half of the year, Minerva Neurosciences Inc. plans to initiate a single phase III trial of lead candidate MIN-101 that will enroll about 500 individuals with schizophrenia to evaluate improvement in negative symptoms. If the trial succeeds, the FDA agreed the data could form the basis – in conjunction with findings from the company's phase IIb trial – for a new drug application (NDA) submission.